Mostrando 10 resultados de: 16
Filtros aplicados
Publisher
Pharmacogenomics(10)
Clinical Chemistry and Laboratory Medicine(1)
Current Drug Targets(1)
Current Topics in Medicinal Chemistry(1)
Drug Metabolism and Personalized Therapy(1)
Área temáticas
Enfermedades(9)
Farmacología y terapéutica(9)
Medicina y salud(8)
Fisiología humana(3)
Psicología diferencial y del desarrollo(3)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(15)
ODS 17: Alianzas para lograr los objetivos(13)
ODS 10: Reducción de las desigualdades(8)
ODS 4: Educación de calidad(4)
ODS 12: Producción y consumo responsables(3)
Origen
scopus(16)
4th ESPT Conference: Pharmacogenomics and personalized medicine - Research progress and clinical implementation
ArticleAbstract: The Fourth European Society of Pharmacogenomics and Personalized Therapy biennial conference was orgPalabras claves:clinical implementation, ESPT conference, personalized medicine, PharmacogenomicsAutores:Adrián LLerena, Ansari M., Cascorbi I., Drago F., Gozzo L., Ingelman-Sundberg M., Katsila T., Manolopoulos V.G., Marc J., Marchetti P., Meyer U.A., Mlakar V., Nofziger C., Paulmichl M., Pearson E., Re M.D., Simmaco M., Sipeky C., Stanković S., Suarez-Kurtz G., Van Schaik R.H.N.Fuentes:scopusCharacterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: Pharmacogenetic implications
ArticleAbstract: CYP2D6 codes for a protein that is vastly involved in the metabolism of various substances. This genPalabras claves:CYP2D6, CYP450, Metabolic profile, pharmacogenetics, Pharmacogenomics, polymorphism, Portuguese populationAutores:Adrián LLerena, Albuquerque J., Grazina M., Naranjo M.E.G., Ribeiro C.Fuentes:scopusClinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
ReviewAbstract: CYP2D6 is described as the most relevant enzyme in the metabolism of many antipsychotic drugs. Its cPalabras claves:Antipsychotic drugs, CYP2D6, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 polymorphism: Implications for antipsychotic drug response, schizophrenia and personality traits
ReviewAbstract: The CYP2D6 gene is highly polymorphic, causing absent (poor metabolizers), decreased, normal or incrPalabras claves:Adverse side effects, antipsychotics, CYP2D6, personality, pharmacogenetics, Pharmacogenomics, QTc, Schizophrenia, vulnerabilityAutores:Adrián LLerena, Dorado P., Penãs-Lledó E.M.Fuentes:scopusCurrent insights into interethnic variability in testicular cancers: Population pharmacogenetics, clinical trials, genetic basis of chemotherapyinduced toxicities and molecular signal transduction
ReviewAbstract: Testicular cancer is an aggressive malignancy with a rising incidence rate across the globe. TesticuPalabras claves:clinical trials, ethnicity, Molecular aspects, pharmacogenetics, Pharmacogenomics, population pharmacogenetics, Precision Medicine, signal transduction, Testicular cancer, Testicular seminoma, Toxicity, Variant polymorphismAutores:Adrián LLerena, de Andrés F., Kothari R., Mishra A., Nair S., Vasistha A.Fuentes:scopusStrengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: The potential value of the PEPs study
ReviewAbstract: The successful application of pharmacogenetics in routine clinical practice is still a long way fromPalabras claves:Antipsychotic, naturalistic studies, pharmacogenetics, Pharmacogenomics, psychiatry, study designsAutores:Adrián LLerena, Bernardo M., Lafuente A., Mas S., Saíz J.Fuentes:scopusSuccess stories in genomic medicine from resource-limited countries
ArticleAbstract: In recent years, the translation of genomic discoveries into mainstream medical practice and publicPalabras claves:ÁFRICA, Economic evaluation in pharmacogenomics, Genetics education, Genome informatics, Genomic medicine, Latin America, Pharmacogenomics, Public health genomics, Southeast AsiaAutores:Adrián LLerena, Al Jaibeji H., Ali B.R., Brand A., Chantratita W., Forero D.A., Laissue P., Lee M.T.M., Lopez-Correa C., Mitropoulos K., Mohamed Z., Patrinos G.P., Wonkam A.Fuentes:scopusThe need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What's next? An urgent clinical unmet need for patients
OtherAbstract:Palabras claves:drug prescription, health services, Implementation, pharmacogenetics, Pharmacogenomics, regulationAutores:Adrián LLerena, Manolopoulos V.G., Rodríguez-Antona C., Stanković S., Taron M., Van Schaik R.H.N.Fuentes:scopusThird Santorini conference pharmacogenomics workshop report: "Pharmacogenomics at the crossroads: What else than good science will be needed for the field to become part of Personalized Medicine?"
Conference ObjectAbstract: This workshop discussed the use of pharmacogenomics knowledge in clinical practice. It was organizedPalabras claves:Education, Industry, personalized medicine, Pharmacogenomics, Regulatory aspectsAutores:Adrián LLerena, Arens H.J., Arnold H.P., Beaune P., Bekers O., Boubekeur K., Donnelly C., Haefliger C., Hockett R.D., Jeannesson E., Junien C., Kaput J., Manolopoulos V.G., McComb J., Michel G., Molloy R., Petrovic N., Siest G., Wong S.Fuentes:scopusWhat is the future of pharmacogenomics in pain management?
OtherAbstract:Palabras claves:Chronic pain, clinical translation, Guidelines, PharmacogenomicsAutores:Adrián LLerena, Margarit C., Peiró A.M.Fuentes:scopus